Synageva Biopharma Corp (GEVA) 238.60 $GEVA Alacrita

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Synageva Biopharma Corp (GEVA) 238.60 $GEVA

Alacrita Appoints Markus Peters to Advise Clients on the Global Commercialization of Early and Late Stage Biopharmaceutical Assets
PR Newswire - Fri Jan 08, 7:00AM CST
Alacrita, the life sciences consulting firm, today announced that it has appointed Markus Peters, PhD, as Associate Partner in its Cambridge, MA office to advise clients on the global commercialization of early and late stage biopharmaceutical assets.
GEVA: 238.60 (+2.80)

CANbridge Appoints Mark A. Goldberg as Acting Chief Medical Officer
BusinessWire - Tue Oct 20, 7:02AM CDT
CANbridge Life Sciences, a biopharmaceutical company focused on developing Western drug candidates in China and North Asia, has appointed Mark A. Goldberg, MD, as Acting Chief Medical Officer (CMO), to take effect immediately.
GEVA: 238.60 (+2.80), IDRA: 1.64 (-0.04)

This Drugmaker's Incredible Run Looks Far From Done
Brian Feroldi, The Motley Fool - Motley Fool - Wed Aug 19, 7:16AM CDT
Photo by Images of Money / Flickr creative commons. "I missed it." I can't tell you how many times I've uttered those words to myself after I look at the long-term chart of a winning stock. When a stock has been a rocket ship over the past one,...
GEVA: 238.60 (+2.80), ALXN: 125.47 (+1.05)

Pompe Disease - Pipeline Review, H1 2015
M2 - Mon Jun 29, 10:49AM CDT
Research and Markets (http://www.researchandmarkets.com/research/d3wrwn/pompe_disease) has announced the addition of the "Pompe Disease - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Pompe Disease, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Pompe Disease and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Mentioned - Amicus Therapeutics, Inc. - Audentes Therapeutics, Inc. - BioMarin Pharmaceutical Inc. - Cortex Pharmaceuticals, Inc. - EpiVax, Inc. - Genzyme Corporation - Oxyrane Belgium NV - Pharming Group N.V. - Sarepta Therapeutics, Inc. - Synageva BioPharma Corp. For more information visit http://www.researchandmarkets.com/research/d3...pe_disease
GEVA: 238.60 (+2.80), BMRN: 89.65 (-1.84), SRPT: 22.42 (-0.20), FOLD: 6.00 (unch)

Mucopolysaccharidosis III (MPS III) (Sanfilippo Syndrome) - Pipeline Review, H1 2015
M2 - Mon Jun 29, 9:16AM CDT
Research and Markets (http://www.researchandmarkets.com/research/jfsvdb/mucopolysaccharido) has announced the addition of the "Mucopolysaccharidosis III (MPS III) (Sanfilippo Syndrome) - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Mucopolysaccharidosis III (MPS III) (Sanfilippo Syndrome), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Mucopolysaccharidosis III (MPS III) (Sanfilippo Syndrome) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Mentioned - ArmaGen Technologies, Inc. - Axcentua Pharmaceuticals AB - BioMarin Pharmaceutical Inc. - Dorphan S.A. - Laboratorios Del Dr. Esteve S.A. - Shire Plc - Synageva BioPharma Corp. - uniQure N.V. For more information visit http://www.researchandmarkets.com/research/jf...saccharido
GEVA: 238.60 (+2.80), BMRN: 89.65 (-1.84), SHPG: 187.47 (-0.74)

5 Healthy Stocks in the Top Biotech ETF - ETF News And Commentary
Sweta Killa - ZACKS - Wed Jun 17, 2:30AM CDT
We have highlighted the five best performing stocks in the top biotech ETF that more than doubled so far this year.
SBIO: 23.85 (+0.23), HALO: 9.17 (+0.06), GEVA: 238.60 (+2.80), IMGN: 3.08 (-0.12), HZNP: 19.15 (+0.44), ANAC: 99.06 (-0.14)

Lysosomal Storage Disorder Pipeline Review, H1 2015 - 15 Companies & 27 Drug Profiles
M2 - Thu Jun 11, 10:11AM CDT
Research and Markets (http://www.researchandmarkets.com/research/vxz52s/lysosomal_storage) has announced the addition of the "Lysosomal Storage Disorder - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Lysosomal Storage Disorder, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Lysosomal Storage Disorder and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Amicus Therapeutics, Inc. - AngioChem Inc. - BBB Therapeutics B.V. - Chiesi Farmaceutici SpA - Fate Therapeutics, Inc. - Minoryx Therapeutics s.l. - Neuralstem, Inc. - Nuo Therapeutics, Inc. - Orphazyme ApS - Oxyrane Belgium NV - REGiMMUNE Corporation - Sagetis Biotech, S.L. - Sangamo BioSciences, Inc. - Synageva BioPharma Corp. - Ultragenyx Pharmaceutical Inc. Drug Profiles - 2B3-201 - ALD-601 - Chaperone-ERT Combinations - Delta-tocopherol - FT-1050 - ML-SA1 - NSI-566 - Orph-001 - Recombinant Enzyme for Farber Disease and Cystic Fibrosis - Recombinant Enzyme for LSD-2 Disease - Recombinant Enzyme for LSD-3 Disease - Recombinant Enzyme for LSD-4 Disease - Recombinant Enzyme for LSD-5 Disease - Recombinant Enzyme for Lysosomal Storage Disorder - Recombinant Enzyme to Activate LRP1 for Lysosomal Storage Disorder - RGI-5000 - SAG-002 - SBLSD-3 - SBLSD-4 - sebelipase alfa - Small Molecule to Activate Beta-Galactosidase for GM1 Gangliosidosis and Gaucher's disease - Small Molecules for GM1-gangliosidosis And Morquio B - Small Molecules for Lysosomal Storage Disorders - Stem Cell Therapy for Lysosomal Storage Disorder - UX-002 - UX-004 - ZA-011 For more information visit http://www.researchandmarkets.com/research/vx...al_storage
FATE: 1.73 (-0.04), GEVA: 238.60 (+2.80), SGMO: 6.09 (-0.09), FOLD: 6.00 (unch), CUR: 0.29 (unch)

Synageva BioPharma Completes Targeted Enrollment in Phase 1/2 Trial with SBC-103 for Mucopolysaccharidosis IIIB
PR Newswire - Thu Jun 04, 3:05PM CDT
Synageva BioPharma Corp. (NASDAQ: GEVA), a biopharmaceutical company developing therapeutic products for rare disorders, today announced the completion of enrollment in a Phase 1/2 trial with SBC-103 in patients with mucopolysaccharidosis IIIB (MPS IIIB, also known as Sanfilippo B syndrome).
GEVA: 238.60 (+2.80)

Fabry Disease Pipeline Review, H1 2015 Edition
M2 - Thu Jun 04, 8:59AM CDT
Research and Markets (http://www.researchandmarkets.com/research/9l8prv/fabry_disease) has announced the addition of the "Fabry Disease - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Fabry Disease, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Fabry Disease and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Amicus Therapeutics, Inc. - Biosidus S.A. - Genzyme Corporation - greenovation Biotech GmbH - iBio, Inc. - ISU ABXIS Co.,Ltd. - JCR Pharmaceuticals Co., Ltd. - Neuraltus Pharmaceuticals, Inc. - Pharming Group N.V. - Protalix BioTherapeutics, Inc. - Synageva BioPharma Corp. Drug Profiles - (migalastat hydrochloride agalsidase alfa) - agalsidase alfa - agalsidase beta biosimilar - Alpha-Galactosidase - Genz-682452 - GZ-402671 - JR-051 - migalastat hydrochloride - Next Generation biologics for Pompe, Fabry and Hunter - NP-003 - PRX-102 - Recombinant Enzyme to Replace Alpha-Galactosidase A for Fabry's Disease For more information visit http://www.researchandmarkets.com/research/9l...ry_disease
GEVA: 238.60 (+2.80), IBIO: 0.69 (+0.01), FOLD: 6.00 (unch)

SHAREHOLDER ALERT: Brodsky & Smith, LLC Announces Investigation of The Board of Directors of Synageva BioPharma Corp.
BusinessWire - Tue Jun 02, 6:29PM CDT
Law office of Brodsky & Smith, LLC announces that it is investigating potential claims against the Board of Directors of Synageva BioPharma Corp. ("Synageva" or "the Company" (Nasdaq: GEVA) for possible breaches of fiduciary duty and other violations of state law in connection with the sale of the Company to Alexion Pharmaceuticals, Inc. ("Alexion" .
GEVA: 238.60 (+2.80), ALXN: 125.47 (+1.05)

Alexion satisfies Hart-Scott-Rodino waiting period for proposed acquisition of Synageva
M2 - Mon Jun 01, 3:24AM CDT
Biopharmaceutical company Alexion Pharmaceuticals (Nasdaq:ALXN) said on Friday that it has met the US Federal Trade Commission's (FTC) early termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (HSR Act) with respect to its planned acquisition of Synageva BioPharma (Nasdaq:GEVA).
GEVA: 238.60 (+2.80), ALXN: 125.47 (+1.05)

Alexion and Synageva Announce Early Termination of Hart-Scott-Rodino Waiting Period for Alexion's Pending Acquisition of Synageva
BusinessWire - Fri May 29, 3:20PM CDT
Alexion Pharmaceuticals, Inc. (Nasdaq:ALXN) and Synageva BioPharma Corp. (Nasdaq:GEVA) today announced that the U.S. Federal Trade Commission (FTC) has granted early termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (HSR Act) with respect to Alexion's pending acquisition of Synageva. The waiting period was scheduled to expire on June 15, 2015.
GEVA: 238.60 (+2.80), ALXN: 125.47 (+1.05)

Synageva BioPharma Files for Kanuma's Approval in Japan - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed May 27, 11:30AM CDT
Synageva BioPharma Corp. (GEVA) submitted its New Drug Application (NDA) for Kanuma (sebelipase alfa) in Japan for the treatment for patients suffering from lysosomal acid lipase deficiency.
VRX: 23.29 (+0.04), GEVA: 238.60 (+2.80), GILD: 86.85 (+0.30), ALXN: 125.47 (+1.05)

Synageva BioPharma Submits Kanuma(TM) (Sebelipase Alfa) Application For LAL Deficiency In Japan
PR Newswire - Tue May 26, 3:05PM CDT
Synageva BioPharma Corp. (NASDAQ: GEVA), a biopharmaceutical company developing therapeutic products for rare disorders, today announced the submission of a New Drug Application (NDA) to the Ministry of Health, Labour and Welfare (MHLW) in Japan for Kanuma(TM) (sebelipase alfa) as a treatment for patients with lysosomal acid lipase deficiency (LAL Deficiency). Upon approval, Kanuma would be the first approved therapy for these patients.
GEVA: 238.60 (+2.80)

SHAREHOLDER ALERT: Brodsky & Smith, LLC Announces Investigation of The Board of Directors of Synageva BioPharma Corp. -GEVA
PR Newswire - Fri May 22, 10:26AM CDT
Law office of Brodsky & Smith, LLC announces that it is investigating potential claims against the Board of Directors of Synageva BioPharma Corp. ("Synageva" or "the Company" (Nasdaq -GEVA-News) for possible breaches of fiduciary duty and other violations of state law in connection with the sale of the Company to Alexion Pharmaceuticals, Inc. ("Alexion" .
GEVA: 238.60 (+2.80), ALXN: 125.47 (+1.05)

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Synageva BioPharma Corp. of Commencement of an Investigation In Connection With the Fairness of the Sale of the Company to Alexion Pharmaceuticals, Inc. -- GEVA
PR Newswire - Mon May 18, 3:10PM CDT
The following statement is being issued by Levi & Korsinsky, LLP:
GEVA: 238.60 (+2.80), ALXN: 125.47 (+1.05)

SYNAGEVA BIOPHARMA CORP. INVESTOR ALERT: Faruqi & Faruqi, LLP Announces the Investigation of Synageva BioPharma Corp. Over the Proposed Sale of the Company to Alexion Pharmaceuticals, Inc.
BusinessWire - Mon May 18, 1:28PM CDT
Juan E. Monteverde, a partner at Faruqi & Faruqi, LLP, a leading national securities firm headquartered in New York City, is investigating the Board of Directors of Synageva BioPharma, Inc. ("Synageva" or the "Company" (Nasdaq: GEVA) for potential breaches of fiduciary duties in connection with the sale of the Company to Alexion Pharmaceuticals, Inc. ("Alexion" (Nasdaq: ALXN) for approximately $8.4 billion in a cash and stock transaction. The deal gives Synageva shares a total value of $226; $115 of which will be paid in cash, while the remaining $111 will be paid for in Alexion stock.
GEVA: 238.60 (+2.80), ALXN: 125.47 (+1.05)

SHAREHOLDER ALERT: Brower Piven Commences An Investigation Into The Proposed Sale Of Synageva BioPharma Corp. And Encourages Investors To Contact The Firm For Additional Information
BusinessWire - Wed May 13, 3:37PM CDT
The securities litigation law firm of Brower Piven, A Professional Corporation, has commenced an investigation into possible breaches of fiduciary duty and other violations of state law by the Board of Directors of Synageva BioPharma Corp. ("Synageva" or the "Company" (Nasdaq: GEVA) relating to the proposed buyout of the Company by Alexion Pharmaceuticals, Inc.
GEVA: 238.60 (+2.80)

Scroll down for more posts ▼

Top 10 Most Recent News Articles

UAE Ties Diplomacy, Media and AI Into a Shared Signal

Updated Category News Views 128

Influence is getting harder to measure, and easier to squander, which is why the message from Ajman deserves more than a polite nod. At the 2026 Ajman Media Forum, THE SIGNAL, Foreign Affairs Undersecretary Omar Obaid Alhesan Alshamsi made the UAE’s position plain: diplomacy and media are no longer separate lanes. Both operate on words, context, trust and the difficult...

Continue Reading
UAE Trust Model Faces Its Hardest Test During Crisis

Updated Category News Views 394

A country’s reputation is usually invisible right up until the machinery rattles. Then people, investors, trading partners and residents stop listening to polished slogans and start watching whether airports function, services hold up, information arrives, and business can keep moving. That was the useful core of Saeed Al Eter’s remarks at Ajman Media Forum 2026: soft...

Continue Reading
DKSH's Vietnam Oncology Pact Carries Real Promise, Risk

Updated Category News Views 58

A cancer-market announcement ought to make investors pause before they reach for a spreadsheet. Specialised Therapeutics and DKSH have signed an exclusive partnership to bring oncology therapies into Vietnam, and the human case is painfully clear: the country recorded an estimated 180,000 new cancer cases and more than 120,000 deaths annually in the 2022 GLOBOCAN data....

Continue Reading
NatGasHub’s 391% Growth Signals a Real Pipeline Shift

Updated Category News Views 459

Three hundred-plus pipelines is a lot of messy plumbing to tame, and NatGasHub has apparently found a lucrative way to do it. The Houston software company landed at No. 182 on Deloitte’s 2026 Technology Fast 500 after reporting 391% revenue growth from 2022 through 2025. That is a serious number, even in a ranking built to showcase companies sprinting uphill. More...

Continue Reading
AutoShop Answers Extends 2027 Training Into Fridays

Updated Category News Views 83

A repair bay can hum all day while the back office quietly bleeds profit. That unglamorous reality is why AutoShop Answers adding nine Friday specialty classes to its 2027 Key2Key Weekend calendar deserves a closer look. This is not a new tool chest or some vague motivational roadshow; it is an attempt to give independent shop owners an extra day to work on the pieces...

Continue Reading
CARsgen's CT1182 Data Opens a Careful New CAR-T Test

Updated Category News Views 140

Six very sick lymphoma patients are not a victory lap, but they can still make the whole cell-therapy field sit up straighter. CARsgen has disclosed first clinical results for CT1182, an in vivo CAR-T candidate built on its CARvivo platform, and the early package is plainly more interesting than the usual preclinical chest-thumping. The company reported three complete...

Continue Reading
Mission Inn’s Lights Enter a Tender New Ownership Era

Updated Category News Views 661

A holiday spectacle can outlive the hands that hung its first bulb. Riverside is about to test that truth in public, under millions of tiny lights and the very large shadow of a family departure. The Mission Inn Festival of Lights returns in 2026 without Kelly and Duane Roberts as hotel owners for the first time in more than three decades. Duane Roberts died in 2025, the...

Continue Reading
PHONO's 150 MW RE+ Win Tests Its U.S. Solar Staying Power

Updated Category News Views 570

A trade-show order book is not cash in the bank, but 150 MW is still a number worth circling in red. PHONO used RE+ 2026 in Las Vegas, held November 17 through 19, to celebrate 20 years in business, parade its solar and storage lineup, and announce new U.S. orders. In a solar market that has become touchier about provenance, compliance and delivered economics, the company...

Continue Reading
Ajman Memory Gives Heritage a Durable Digital Backbone

Updated Category News Views 318

Archives usually get applause only after somebody realizes a piece of history has vanished. Ajman is trying to skip that miserable part. During the Ajman Media Forum 2026, held November 18 and 19 at the Emirates Hospitality Centre, the emirate launched Ajman Memory, a project built to collect, document and preserve photographs, papers and video recording its development....

Continue Reading
Luca's Campo Morado Denial Makes Guerrero Risk Clear

Updated Category News Views 19

A Dangerous Headline Needs More Than a Quick Rebuttal One ugly allegation can do more damage to a junior miner than a lousy quarter, especially when it involves a mine in Guerrero State and alleged criminal control. Luca Mining has flatly rejected Mexican media reports claiming that its Campo Morado Mine is controlled by a criminal organization. The company says the...

Continue Reading

Top 5 Most Recently Viewed Articles

Leidos' Autonomous Vessels Chart Bold Naval Waters

Updated Category News Views 49

Leidos' Autonomous Leap with the U.S. Navy Well, today it's all about Leidos, an outfit that's been showing its grit in the world of maritime autonomy. Their systems aren't just tinkering around anymore—they're slicing through the waves at RIMPAC, the Rim of the Pacific, and running alongside the USS Theodore Roosevelt Carrier Strike Group. That's big news in anyone's...

Continue Reading
89bio to Showcase Pegozafermin Trial Insights at Major Conference

Updated Category News Views 67

89bio Presents Key Findings from ENLIVEN Phase 2b Trial 89bio, Inc. (NASDAQ: ETNB), a biopharmaceutical company committed to developing innovative treatments for liver and cardiometabolic diseases, has exciting news. The company will present new analyses from its Phase 2b ENLIVEN trial, which assesses the efficacy of pegozafermin in patients suffering from metabolic...

Continue Reading
New Insights on Penetrium's Role in Combating TNBC Growth

Updated Category News Views 487

Hyundai ADM Bio Unveils Promising Results for Penetrium – Groundbreaking treatment strategy targets both primary and metastatic tumors. Hyundai ADM Bio has announced significant findings related to its pioneering agent, Penetrium, which exhibited impressive anti-metastatic properties in recent preclinical studies involving triple-negative breast cancer (TNBC). This...

Continue Reading
Designer Brands Inc. Reveals Upcoming Earnings Call for Q1 2025

Updated Category News Views 178

Upcoming Earnings Release for Designer Brands Inc. Designer Brands Inc. (NYSE: DBI), a leading force in footwear and accessories, has announced an important date for shareholders and interested parties alike. The company is set to release its earnings for the first quarter of 2025 on June 10, 2025. This marks a significant event, as it gives insights into the company's...

Continue Reading
Harvard Bioscience, Inc. Reports Q1 2025 Financial Performance

Updated Category News Views 374

Strong Financial Insights from Harvard Bioscience Harvard Bioscience, Inc. (NASDAQ: HBIO) recently shared its financial results for the first quarter, showcasing a mixed performance influenced by various market factors. The company expressed confidence in its revenue management and highlighted new product developments that are energizing its business strategies. Revenue...

Continue Reading